Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

To Evaluate the Dose Response of 3 Doses of Euphorbia Prostrata in Patients With First and Second Degree Hemorrhoids

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Panacea Biotec Ltd
ClinicalTrials.gov Identifier:
NCT01041911
First received: December 31, 2009
Last updated: December 4, 2012
Last verified: December 2012

December 31, 2009
December 4, 2012
March 2010
October 2010   (final data collection date for primary outcome measure)
Proportion of subjects in each treatment group achieving cessation of per rectal bleeding as assessed by the subject [ Time Frame: 14 day of treatment ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01041911 on ClinicalTrials.gov Archive Site
Proportion of subjects in each treatment group without recurrence of bleeding [ Time Frame: 14 days post treatment ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
To Evaluate the Dose Response of 3 Doses of Euphorbia Prostrata in Patients With First and Second Degree Hemorrhoids
Double-blind, Randomized, Placebo-controlled, Dose Response Study to Evaluate the Safety and Efficacy of Three Doses of Euphorbia Prostrata Dry Extract Tablets in Patients of Hemorrhoids

The purpose of this study is to determine the safe and efficacious dose of Euphorbia prostrata for control of per rectal bleeding in patients with first and second degree hemorrhoids.

Hemorrhoidal disease is a common entity in the general population and in clinical practice. The basic pathological factor in hemorrhoids is the dilation of the anorectal venous plexuses. In the acute bleeding of internal hemorrhoids, one of the pathogenic processes implicated is the stagnation and stasis of blood in the vascular plexuses of the prolapsed anal cushions. Euphorbia prostrata extract is found to have antihemorrhoidal activity and is useful in ameliorating signs and symptoms associated with hemorrhoids.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Hemorrhoids
  • Drug: Euphorbia tablets
    50 mg, tablet, once daily, 14 days
    Other Name: To be confirmed later
  • Drug: Euphorbia tablets
    100 mg, tablet, once daily, 14 days
    Other Name: To be confirmed later
  • Drug: Euphorbia tablets
    200 mg, tablet, 2 tablets of 100 mg Euphorbia prostrata, 14 days
    Other Name: To be confirmed later
  • Drug: Placebo tablets
    placebo, tablet, once daily, 14 days
  • Active Comparator: Euphorbia 50 mg
    This arm subjects will be given 50 mg Euphorbia prostrata
    Intervention: Drug: Euphorbia tablets
  • Active Comparator: Euphorbia 100 mg
    In this arm subjects will be given 100 mg Euphorbia
    Intervention: Drug: Euphorbia tablets
  • Active Comparator: Euphorbia 200 mg
    In this arm subject will be given 200 mg Euphorbia tablets
    Intervention: Drug: Euphorbia tablets
  • Placebo Comparator: Placebo
    In this arm subjects will be given placebo tablets
    Intervention: Drug: Placebo tablets
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
102
November 2010
October 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Adult subjects who are able to understand nature, significance and scope of the clinical trial and express their will accordingly and agreeing to participate in the study by giving written informed consent.
  • Male or female subjects, at least 18 years of age with a diagnosis of internal hemorrhoids (first and second degree) confirmed by proctoscopic examination and suffering from an uncomplicated and untreated acute attack (defined as acute onset of per rectal bleeding within 3 days of inclusion into the study, with at least one of the symptoms viz. pain, tenesmus, pruritus and anal discharge).
  • Except internal hemorrhoids (first and second degree), the subjects are judged to be in good general health, based on medical history, physical examination, and laboratory screening tests.

Exclusion Criteria:

  • Pregnant and lactating women and women in post-partum period of up to 6 weeks.
  • Women of child bearing potential who do not agree to remain abstinent or use medically acceptable methods of contraception during the study therapy and for 4 weeks after the end of study therapy.
  • Subjects who have been previously enrolled in a study involving E. prostrata Dry Extract
  • Subjects with a history of permanent anal prolapse and/or anal fistula
  • Subjects with associated anal fissures and/or infective anal pathology.
  • Subjects with previous history of surgery for anorectal disease (within 5 years) or any other procedures (including but not limited to injection sclerotherapy, rubber band ligation, photocoagulation, cryotherapy etc) within 2 year of enrolment into the trial.
  • Subjects who, in the opinion of the investigator, are mentally incapacitated such that informed consent cannot be obtained.
  • Subjects with clinically significant co-morbid condition that in the opinion of the investigator could affect the efficacy and safety outcome of the study.
  • Subjects with clinically significant laboratory values for hemoglobin, total leukocyte count, differential count, bleeding time, clotting time, PT/INR, aPTT/control, platelet count, SGOT, SGPT, alkaline phosphatase, total bilirubin, random blood sugar, serum cholesterol, blood urea, serum creatinine and urine routine and microscopic examination.
  • Treatment with any of the following at inclusion or in the previous one month venotropic, anticoagulant, and anti platelet agent. Subjects on aspirin up to 160 mg for cardiovascular indication will not be excluded from the trial.
  • Treatment with any of the following at inclusion or in the previous one week anti-inflammatory and analgesic agent.
  • Other chronic medications not being used at a stable dosage for at least 2 weeks.
  • Subjects who are current users of illicit drugs including "recreational use" or with a history of drug abuse within the past 5 years.
  • Subjects who have donated a unit of blood or plasma or participated in another clinical study with an investigational agent within the last 12 weeks
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
India
 
NCT01041911
PBL/CR/0102008/CT
No
Panacea Biotec Ltd
Panacea Biotec Ltd
Not Provided
Principal Investigator: Dr P N Agarwal Maulana Azad Medical College, New Delhi
Principal Investigator: Dr Girish Bakshi Grant Medical College, Mumbai
Principal Investigator: Dr T Durganna Bangalore Medical College, Bangalore
Principal Investigator: Dr Saiprasad Donga Sahil Hospital, Tawdw Niwas, 1st Floor Khopat, Thane
Principal Investigator: Dr Vaibhav Lokhande Nath Hospital, Golden Heaven Society, Opp Janta Sahakari Bank, Khopat, Thane
Principal Investigator: Dr P S Sarangi Deen Dayal Upadhyay Hospital, Hari Nagar, New Delhi
Panacea Biotec Ltd
December 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP